Clinical Trials Logo

Clinical Trial Summary

This study tests a new medication for treatment of kidney cancer, called BEZ235. This medication works by blocking several mechanisms that the cancer needs to grow and survive. By blocking these mechanisms, the medication can thus suppress further growth of the cancer, possibly kill cancer cells. Older kidney cancer medications (such as temsirolimus [Torisel®] or everolimus [Afinitor®]) typically only block one mechanism in cancer cells, so the investigators think that BEZ235 may work even better against kidney cancer.

The purpose of the first part of this study is to test the safety of giving BEZ235 at different doses. The investigators are trying to find a safe dose of BEZ235 and want to find out what effects, good and/or bad, it has on the patient and the cancer.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01453595
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date October 2011
Completion date April 2014

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT00531284 - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1/Phase 2
Recruiting NCT05842044 - NSAID Use After Robotic Partial Nephrectomy Phase 2
Recruiting NCT05387863 - Decision Aid (DA) for Renal Patients N/A
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Withdrawn NCT03390413 - Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer N/A
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT03203473 - Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Phase 2
Suspended NCT04115254 - Stereotactic Magnetic Resonance Guided Radiation Therapy N/A
Enrolling by invitation NCT02609269 - Decipher Genomics Resource for Intelligent Discovery
Completed NCT01444456 - Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia N/A
Completed NCT02811250 - Stereotactic Radiotherapy for Renal Cancers N/A
Completed NCT00399152 - Perifosine + Sunitinib Malate for Patients With Advanced Cancers Phase 1
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1
Completed NCT00458536 - Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Phase 1/Phase 2
Recruiting NCT03693014 - A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors Phase 2
Completed NCT00418496 - Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Phase 1
Recruiting NCT06051162 - HPI Effect in Robotic Urological Surgery on AKI N/A